In systemic ANCA-positive vasculitides, does therapeutic management include intravenous cyclophosphamide induction, anti‑TNFα (anti‑tumor necrosis factor‑alpha) biological agents, high‑dose intravenous corticosteroid therapy during the first six months, maintenance therapy with azathioprine or mycophenolate mofetil, and management of cardiovascular risk factors?

Therapeutic Management of Systemic ANCA-Positive Vasculitides

The therapeutic management of systemic ANCA-positive vasculitides includes induction therapy with cyclophosphamide (oral or intravenous), corticosteroid therapy with rapid tapering (not high-dose for six months), maintenance therapy with azathioprine or mycophenolate mofetil, and management of cardiovascular risk factors; anti-TNFα biological agents are NOT part of standard therapy. 1, 2

Evaluating Each Component:

a) Induction Therapy with Intravenous Cyclophosphamide: TRUE

Cyclophosphamide (either intravenous or oral) is a cornerstone of induction therapy for ANCA-associated vasculitis (AAV). The 2024 KDIGO guidelines recommend glucocorticoids combined with either rituximab or cyclophosphamide for initial treatment of new-onset AAV 1. The EULAR 2022 guidelines similarly recommend this combination for organ-threatening or life-threatening disease 2.

Dosing specifics:

• Intravenous cyclophosphamide: 15 mg/kg at weeks 0,2,4,7,10,13 (with additional doses at weeks 16,19,21,24 if required) 1
• Oral cyclophosphamide: 2 mg/kg/day for 3 months, continuing for ongoing activity up to a maximum of 6 months 1
• Age-based dose reductions are mandatory: reduce to 1.5 mg/kg/day at age >60 years and 1.0 mg/kg/day at age >70 years 1

Important caveat: While both routes are effective, intravenous cyclophosphamide is preferred for patients with prior cyclophosphamide exposure, lower white blood cell counts, or adherence concerns 1.

b) Anti-TNFα Biological Agents: FALSE

Anti-TNFα agents are NOT part of standard therapeutic management for ANCA-associated vasculitis. Neither the 2024 KDIGO guidelines 1 nor the 2022 EULAR guidelines 2 recommend anti-TNFα therapy as standard treatment. While older literature mentions TNF-α blockers as options for refractory disease 3, 4, they have not been validated in high-quality trials and are not included in current evidence-based guidelines.

The standard biologics for AAV are rituximab (preferred for relapsing disease) and avacopan (as a glucocorticoid alternative), not anti-TNFα agents 1, 2.

c) Intravenous High-Dose Corticosteroid Therapy During the First Six Months: FALSE

This statement is misleading and incorrect regarding duration and dosing strategy. The current evidence-based approach emphasizes rapid glucocorticoid tapering, not sustained high-dose therapy for six months.

The correct corticosteroid regimen:

• Starting dose: 50-75 mg prednisolone equivalent daily (weight-based: 50 mg for <50 kg, 60 mg for 50-75 kg, 75 mg for >75 kg) 1, 2
• Rapid taper: By weeks 5-6, reduce to 15-25 mg daily; by weeks 11-12, reduce to 7.5-12.5 mg daily 1
• Target by 4-5 months: 5 mg prednisolone equivalent per day 2
• Long-term maintenance: 5-7.5 mg/day for 2 years, then slowly reduced by 1 mg every 2 months 1

The PEXIVAS trial demonstrated that reduced-dose glucocorticoid regimens are as effective as standard regimens with lower toxicity 1. Prolonged high-dose corticosteroids increase infection risk and other complications without additional benefit.

d) Maintenance Therapy with Azathioprine or Mycophenolic Acid: TRUE

Maintenance therapy with azathioprine or mycophenolate mofetil (MMF) is recommended after achieving remission. The 2024 KDIGO guidelines recommend maintenance therapy with either rituximab, or azathioprine and low-dose glucocorticoids after induction of remission 1.

Dosing and duration:

• Azathioprine: 1.5-2 mg/kg/day at complete remission, maintained until 1 year after diagnosis, then decreased by 25 mg every 3 months 1
• Extended regimen: Continue at 1.5-2 mg/kg/day for 18-24 months, then decrease to 1 mg/kg/day until 4 years after diagnosis 1
• Mycophenolate mofetil: 2000 mg/day (divided doses) at complete remission for 2 years 1

Important considerations:

• MMF or methotrexate are alternatives for patients intolerant of azathioprine 1
• Methotrexate should NOT be used if GFR <60 ml/min/1.73 m² 1
• Optimal duration of maintenance therapy is 18 months to 4 years after induction of remission 1
• Rituximab is now preferred over azathioprine for maintenance, particularly in relapsing disease 1, 2

e) Management of Cardiovascular Risk Factors: TRUE

Management of cardiovascular risk factors is an essential component of AAV care. The 2022 EULAR guidelines explicitly state in Overarching Principle C: "Patients with AAV should be periodically screened for treatment-related adverse effects and comorbidities. We recommend prophylaxis and lifestyle advice to reduce treatment-related complications and other comorbidities" 2.

Rationale:

• Patients with AAV have increased cardiovascular risk due to systemic inflammation, endothelial dysfunction, and glucocorticoid exposure
• Long-term glucocorticoid therapy increases risks of hypertension, diabetes, dyslipidemia, and osteoporosis
• Cyclophosphamide and other immunosuppressants contribute to metabolic complications

Practical management includes:

• Blood pressure monitoring and control
• Lipid management
• Diabetes screening and management
• Osteoporosis prevention (calcium, vitamin D, bisphosphonates when indicated)
• Smoking cessation
• Regular cardiovascular risk assessment

Common Pitfalls to Avoid:

1. Do not continue high-dose glucocorticoids beyond the initial weeks - rapid tapering is evidence-based and reduces toxicity 1, 2
2. Do not use methotrexate for maintenance if GFR <60 ml/min/1.73 m² - this is contraindicated 1
3. Do not forget age-based cyclophosphamide dose reductions - failure to adjust increases toxicity risk 1
4. Do not assume anti-TNFα agents are standard therapy - they are not recommended in current guidelines 1, 2
5. Do not neglect cardiovascular risk factor management - this is integral to comprehensive AAV care 2